

Date 4th March 2010

Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 6NA



Quarry House
Quarry Hill
Leeds
LS2 7UE

Tel: 0113 254 5000

Dear [REDACTED]

Patient Access Scheme – Mepact (mifamurtide)

I am writing to confirm the Department of Health's position on the Patient Access Scheme (PAS) arrangements that have been proposed by Takeda for Mepact (mifamurtide) in the treatment of non-metastatic osteosarcoma indicated in children, adolescents and young adults.

The Department is content for NICE to consider the PAS proposed by Takeda.

Yours sincerely

[REDACTED]

Medicines, Pharmacy and Industry Group